Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.715
-0.114 (-13.73%)
Mar 9, 2026, 1:10 PM EDT - Market open
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$74,571
Profits / Employee
-$1,541,878
Market Cap
17.79M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| Daré Bioscience | 23 |
| Reviva Pharmaceuticals Holdings | 14 |
| Genenta Science | 13 |
| VYNE Therapeutics | 13 |
| NanoViricides | 7 |
| Intensity Therapeutics | 7 |
| Allarity Therapeutics | 7 |
LEXX News
- 5 days ago - Lexaria Announces New R&D Plans for 2026 - Accesswire
- 4 weeks ago - Lexaria Announces Positive Final Results From Human Pilot Study #5 - Accesswire
- 6 weeks ago - Lexaria Awarded Six Additional Patents - Accesswire
- 2 months ago - Lexaria Releases Annual Letter from the CEO - Accesswire
- 2 months ago - Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Accesswire
- 2 months ago - Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
- 2 months ago - Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Accesswire
- 2 months ago - Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire